{"id":480233,"date":"2020-04-20T11:42:01","date_gmt":"2020-04-20T11:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=480233"},"modified":"2020-04-20T11:42:01","modified_gmt":"2020-04-20T11:42:01","slug":"neurofibromatosis-key-pharma-players-involved-and-emerging-therapies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/neurofibromatosis-key-pharma-players-involved-and-emerging-therapies_480233.html","title":{"rendered":"Neurofibromatosis: Key pharma players involved and Emerging therapies"},"content":{"rendered":"
\"Neurofibromatosis:<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
“Neurofibromatosis Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Neurofibromatosis market. A detailed picture of the Neurofibromatosis pipeline landscape is provided, which includes the disease overview and Neurofibromatosis treatment guidelines. <\/div>\n

“Neurofibromatosis Pipeline Insight, 2020<\/a>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Neurofibromatosis market. A detailed picture of the Neurofibromatosis pipeline landscape is provided, which includes the disease overview and Neurofibromatosis treatment guidelines.<\/p>\n

The assessment part of the report embraces in-depth Neurofibromatosis commercial assessment and clinical assessment of the Neurofibromatosis pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neurofibromatosis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

\"\"<\/p>\n

Scope of the report:
<\/strong>1. The Neurofibromatosis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products<\/em> by development stage, product type, route of administration, molecule type, and MOA type for <\/em>Neurofibromatosis across the complete product development cycle, including all clinical and nonclinical stages.
2. It comprises of detailed profiles of <\/em>Neurofibromatosis therapeutic products<\/em> with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
3. Detailed Neurofibromatosis research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.
4. Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across Neurofibromatosis.<\/p>\n

The launch of the emerging therapies is expected to significantly impact the Neurofibromatosis treatment scenario in the upcoming years:-<\/strong>
Drugs covered<\/strong>
1. Selumetinib
2. Binimetinib
3. PD-0325901
And many others<\/p>\n

The key players in Neurofibromatosis market are:<\/strong>
1. AstraZeneca
2. Array Biopharma
3. SpringWorks Therapeutics
And many others<\/p>\n

Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/neurofibromatosis-pipeline-insight<\/strong><\/p>\n

Table of contents:
<\/strong>1. Report Introduction
2. Neurofibromatosis Market Overview at a Glance
3. Neurofibromatosis Disease Background and Overview
4. Neurofibromatosis Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. Neurofibromatosis Geography-wise Prevalent Cases
4.3. United States
4.4. EU-5
4.4.1. Assumptions and Rationale
4.4.2. Germany
4.4.3. France
4.4.4. Italy
4.4.5. Spain
4.4.6. United Kingdom
4.5. Japan
5. Neurofibromatosis Treatments & Medical Practices
6. Key Emerging Therapies
6.1. Key Cross Competition
6.2. Selumetinib: AstraZeneca
6.3. Binimetinib: Array Biopharma
6.4. PD-0325901: SpringWorks Therapeutics
7. Neurofibromatosis Market Size
8. 7MM Neurofibromatosis: Country-Wise Market Analysis
8.1. United States Market Size
8.2. Germany Market Size
8.3. France Market Size
8.4. United Kingdom Market Size
8.5. Spain Market Size
8.6. Italy Market Size
8.7. Japan Market Size
9. Neurofibromatosis Report Methodology
10. Delveinsight Capabilities
11. Disclaimer
12. About DelveInsight<\/p>\n

About DelveInsight:
<\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
<\/strong><\/p>\n

Download free report @<\/strong>https:\/\/www.delveinsight.com\/sample-request\/neurofibromatosis-pipeline-insight<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP “Neurofibromatosis Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Neurofibromatosis market. A detailed picture of the Neurofibromatosis pipeline landscape is provided, which includes the disease … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-480233","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/480233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=480233"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/480233\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=480233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=480233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=480233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}